Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
Launched by GREATER HOUSTON RETINA RESEARCH · Jan 12, 2021
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
This phase 4 study is designed to assess the need for ongoing 2 mg intravitreal aflibercept injections (IAI) for subjects who completed the 2-year PANORAMA (VGFTe-OD-1411) trial for the management of diabetic retinopathy (DR). Sites will be considered for VOYAGE if they have 4 or more subjects from PANORAMA able to participate.
Relevant data from all participating subjects will be collected and reported retrospectively for the period between PANORAMA study exit and VOYAGE study enrollment.
For the prospective portion of the study, eyes will be assigned to 1 of 2 groups, eyes without panre...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Enrolled and completed PANORAMA (VGFTe-OD-1411) clinical trial
- • 2. Willing and able to comply with clinic visits and study-related procedures
- • 3. Provide signed informed consent
- Exclusion Criteria:
- • 1. Any prior systemic anti-vascular endothelial growth factor (VEGF) treatment or IVT anti-VEGF treatment in the study eye within 21 days of baseline
- • 2. Any intra- or periocular corticosteroid treatment in the study eye within 3 months of baseline
- • 3. Any intraocular sustained-release treatment, implantable device, or gene therapy in the study eye
- • 4. Pregnant or breastfeeding women
- • 5. Sexually active men\* or women of childbearing potential\*\* who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening/baseline; intrauterine device (IUD); bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly).
- • Contraception is not required for men with documented vasectomy. \*\*Postmenopausal women must be amenorrhoeic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
About Greater Houston Retina Research
Greater Houston Retina Research is a leading clinical trial sponsor dedicated to advancing the field of retinal health through innovative research and comprehensive clinical studies. With a commitment to improving patient outcomes, the organization collaborates with top-tier medical professionals and institutions to investigate new treatment options for various retinal conditions. By prioritizing patient safety and ethical standards, Greater Houston Retina Research aims to contribute valuable insights to the scientific community while fostering the development of cutting-edge therapies that enhance vision care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oklahoma City, Oklahoma, United States
Winter Haven, Florida, United States
Beverly Hills, California, United States
West Columbia, South Carolina, United States
Harlingen, Texas, United States
Marietta, Georgia, United States
Willow Park, Texas, United States
Hagerstown, Maryland, United States
New Albany, Indiana, United States
Germantown, Tennessee, United States
Bellaire, Texas, United States
Orlando, Florida, United States
Florence, South Carolina, United States
Arecibo, , Puerto Rico
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials